AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
AbbVie and Allergan announced that Allergan has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase). These agreements are in conjunction…
Read More...
Read More...
